PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 23, 2021-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in
Collaboration will focus on UGN-302 as an investigational treatment for high-grade non-muscle invasive bladder cancer PRINCETON, N.J. & HOUSTON --(BUSINESS WIRE)--Jan. 13, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions
PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 6, 2021-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett , President and Chief Executive Officer,
PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 4, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to
Clinically Meaningful Response Underscores Potential for Jelmyto to Become New Standard of Care for Patients with Low-Grade Upper Tract Urothelial Cancer Of the 58% of Patients who Achieved a Complete Response, 12-Month Durability of Response Estimated at 81.8% by Kaplan-Meier Analysis Median Time
65% Complete Response Rate at Three Months Duration of Response Estimated to be 72.5% at Nine Months (12-Months from Initiation of Therapy) by Kaplan-Meier Method ; Median Duration of Response was Not Reached Treatment with UGN-102 was Generally Well Tolerated, with Mostly Mild to Moderate Adverse
PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 11, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has
PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 10, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in
Top-line Results from UGN-102 OPTIMA II Phase 2b Trial Expected by Year End 2020; On Track to Initiate Phase 3 ATLAS Trial by Year End Achieved Jelmyto ® Net Product Revenue of $3.5 Million in First Full Quarter of Commercialization Management Team Expanded to Drive Platform Expansion and Growth
Conference Call and Webcast Scheduled for Monday, November 9, 2020 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 2, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic
